Ascendis Pharma
Update in progressASND (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Ascendis Pharma A/S is a biopharmaceutical company focused on TransCon-based therapies to address unmet medical needs in Europe, the United States and beyond. It markets SKYTROFA for pediatric growth hormone deficiency and YORVIPATH, a once-daily subcutaneous treatment for adults with chronic hypoparathyroidism. The company also advances three endocrinology rare-disease candidates in clinical development and oncology therapies. Founded in 2006, it is based in Hellerup, Denmark.
Company score
- Sentiment
- 0.46
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.37
- Governance
- 0.11
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.13
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.30
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationDenmark
- CEOMr. Jan Moller Mikkelsen
- Founded2006
- Employees1,189
- Websiteascendispharma.com
Identifiers
- ISINUS04351P1012
- FIGIBBG007R7VNC1
- LEI549300B66JN3W3J8GH73
- CUSIP04351P101
- CIK0001612042